Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 1;25(6):399-419.
doi: 10.2459/JCM.0000000000001616. Epub 2024 Apr 26.

Management of hypertrophic cardiomyopathy

Yuhui Zhang  1 , Marianna Adamo  2 , Changhong Zou  1 , Aldostefano Porcari  3 , Daniela Tomasoni  2 , Maddalena Rossi  3 , Marco Merlo  3 , Huihui Liu  1 , Jinxi Wang  1 , Ping Zhou  1 , Marco Metra  2 , Gianfranco Sinagra  3 , Jian Zhang  1
Affiliations
Review

Management of hypertrophic cardiomyopathy

Yuhui Zhang et al. J Cardiovasc Med (Hagerstown). .

Abstract

Hypertrophic cardiomyopathy is an important cause of heart failure and arrhythmias, including sudden death, with a major impact on the healthcare system. Genetic causes and different phenotypes are now increasingly being identified for this condition. In addition, specific medications, such as myosin inhibitors, have been recently shown as potentially able to modify its symptoms, hemodynamic abnormalities and clinical course. Our article aims to provide a comprehensive outline of the epidemiology, diagnosis and treatment of hypertrophic cardiomyopathy in the current era.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Fig. 1
Fig. 1
Diagnostic algorithm for hypertrophic cardiomyopathy (CMR, cardiac magnetic resonance; ECG, electrocardiography; HCM, hypertrophic cardiomyopathy; SCD, sudden cardiac death).
Fig. 2
Fig. 2
Flow chart for genetic testing and family screening in hypertrophic cardiomyopathy (B/LB, benign/likely benign; HCM, hypertrophic cardiomyopathy; P/LP, pathogenic/likely pathogenic; VUS, variant of unknown significance).
Fig. 3
Fig. 3
Flow chart for treatment of patients with hypertrophic cardiomyopathy (CCB, calcicum channel blocker; CRT, cardiac resynchronization therapy; GDMT, guideline-directed medical therapy; HCM, hypertrophic cardiomyopathy; HFpEF, heart failure with preserved ejection fraction; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association).
Fig. 4
Fig. 4
Flow chart for selection of ICD implantation population in patients with hypertrophic cardiomyopathy (HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; SCD, sudden cardiac death).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Elliott PM, Anastasakis A, Borger MA, et al. . 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35:2733–2779. - PubMed
    1. Chinese Heart Failure Association of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Heart Failure and Cardiomyopathy. Chinese guidelines on the management of hypertrophic cardiomyopathy 2017. Chin J Heart Fail Cardiomyopathy 2017; 1:65–86.
    1. Ommen SR, Mital S, Burke MA, et al. . 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2020; 76:3022–3055. - PubMed
    1. Kitaoka H, Tsutsui H, Kubo T, et al. . Japanese Circulation Society Joint Working Group. JCS/JHFS 2018 guideline on the diagnosis and treatment of cardiomyopathies. Circ J 2021; 85:1590–1689. - PubMed
    1. Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J 1958; 20:1–8. - PMC - PubMed

MeSH terms